Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain

Neurology and Therapy

Volumn 3, Issue 2, 2014, Pages 79-88

  Richards, Danielle ^a   Sabbagh, Marwan N ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer s disease; Amyloid imaging; Biomarkers; Florbetaben

Indexed keywords

APOLIPOPROTEIN; BENZOFURAN DERIVATIVE; BENZOXAZOLE DERIVATIVE; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; FLORBETABEN; FLORBETAPIR F 18; FLUORINE 18; FLUORODEOXYGLUCOSE; FLUTEMETAMOL F 18; PIB CARBON 11; RADIOISOTOPE; STILBENE; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BRAIN; CEREBROSPINAL FLUID ANALYSIS; CLINICAL DEMENTIA RATING; DEMENTIA; DIAGNOSTIC PROCEDURE; DRUG HALF LIFE; FUNCTIONAL NEUROIMAGING; GENE MUTATION; GOLD STANDARD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 84977109007     PISSN: 21938253     EISSN: 21936536     Source Type: Journal    
DOI: 10.1007/s40120-014-0022-9     Document Type: Review

References (32)

1. Cummings JL. Alzheimer’s disease. N Engl J Med. 2004;351:56–67.
2. Miniño AM. Death in the United States, 2011. NCHS Data Brief, 115. http://www.cdc.gov/nchs/data/databriefs/db115.htm. Accessed Nov 11, 2014.
3. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3:211–25.
4. Banarjee S, Wittenberg R. Clinical and cost effectiveness of services for early diagnosis and intervention in dementia. Int J Geriatr Psychiatry. 2009;24:748–54.
5. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.
6. Gaugler JE, Kane RL, Johnston JA, Sarsour K. Sensitivity and specificity of diagnostic accuracy in Alzheimer’s disease: a synthesis of existing evidence. Am J Alzheimers Dis Other Demen. 2013;28:337–47.
7. Nair AK, Sabbagh MN. Amyloid imaging. In: Nair AK, Sabbagh MN, editors. Geriatric neurology. Chichester: Wiley-Blackwell; 2014.
8. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29 (Erratum: Lancet Neurol. 2014;13:757).
9. Morinaga A, Ono K, Ikeda T, et al. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer’s Disease in a memory clinic. Dement Geriatr Cogn Disord. 2010;30:285–92.
10. Cure S, Abrams K, Belger M, Dell’agnello G, Happich M. Systematic literature review and meta-analysis of diagnostic test accuracy in Alzheimer’s Disease and other dementia using autopsy as standard of truth. J Alzheimers Dis. 2014;42:169–82.
11. Fleisher AS, Drzezga A. Functional Imaging in Dementia. In: Nair AK, Sabbagh MN, editors. Geriatric neurology. Chichester: Wiley-Blackwell; 2014.
12. Mason NS, Mathis CA, Klunk WE. Positron emission tomography radioligands for in vivo imaging of Aβ plaques. J Labelled Comp Radiopharm. 2013;56:89–95.
13. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733–40.
14. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer’s disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83:923–6.
15. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.
16. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.
17. Johnson KA, Sperling RA, Gidicsin CM, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9:S72–83.
18. Siderowf A, Pontecorvo MJ, Shill HA, et al. PET imaging of amyloid with Florbetapir F18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders. BMC Neurol. 2014;14:79.
19. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913–20.
20. Johnson KA, Minoshima S, Bohnen NI, Alzheimer’s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9:e-1–16.
21. Clark CM, Schneider JA, Bedell BJ, AV45-A07 Study Group, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275–83.
22. Lundqvist R, Lilja J, Thomas BA, et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med. 2013;54:1472–8.
23. Leinonen V, Rinne JO, Virtanen KA, et al. Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. Eur J Neurol. 2013;20:1043–52.
24. Barthel H, Sabri O. Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET. J Alzheimers Dis. 2011;26:117–21.
25. Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol. 2005;32:799–809.
26. Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A. Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain. 2013;136:2217–27.
27. Ong K, Villemagne VL, Bahar-Fuchs A, et al. (18)F-florbetaben Aβ imaging in mild cognitive impairment. Alzheimers Res Ther. 2013;5:4.
28. Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210–7.
29. Barthel H, Luthardt J, Becker G, et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011;38:1702–14.
30. Barthel H, Gertz HJ, Dresel S, et al. Florbetaben Study Group. (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35.
31. Villemagne VL, Mulligan RS, Pejoska S, et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39:983–9.
32. Ong KT, Villemagne VL, Bahar-Fuchs A, et al. Aβ imaging with 18F-florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2014. doi:10.1136/jnnp-2014-308094